SHR-3167

SHR-3167 is an investigational injectable from Jiangsu Hengrui Medicine, China's largest pharma, being developed for type 2 diabetes (T2D). Hengrui hasn't publicly disclosed the molecular class, but the trial program reads exactly like a long-acting basal insulin analog: two Phase 2 studies pitting SHR-3167 against the two dominant basal insulins on the market today, glargine (Sanofi's Lantus/Toujeo) and degludec (Novo Nordisk's Tresiba) [1][2]. Both Phase 2s use HbA1c reduction as the primary endpoint (20 weeks for the insulin-naïve study, 16 weeks for the switch study), the standard regulatory yardstick for basal insulins. Why this matters: the global basal insulin market was approximately $19B in 2025 (projected to grow toward $38B by 2032), with Novo Nordisk, Sanofi, and Eli Lilly supplying ~90% of global volume [10]. Hengrui is moving to plant a flag in this market even as those incumbents pivot toward once-weekly insulins: Novo's icodec (Awiqli) received EMA marketing authorization in May 2024 after a positive CHMP opinion on March 21, 2024 [7], and Lilly's efsitora alfa completed its QWINT Phase 3 program in 2025 with Lilly publicly committing to US/EU/Japan regulatory submissions by year-end 2025 [8]. SHR-3167 looks like a daily basal, which puts it in a defensive position against the weekly disruptors. Strong commercial play in China, harder sell ex-China unless the PK profile differentiates.

Two Phase 2 trials in China, both ACTIVE_NOT_RECRUITING, meaning enrollment is closed and readouts are pending. NCT06688123 randomizes 275 insulin-naive T2D patients inadequately controlled on metformin alone or in combination with SGLT2 inhibitors to SHR-3167 (two dose levels) versus insulin glargine, 20-week primary endpoint on HbA1c [1]. NCT07018453 enrolls 173 T2D patients already on basal insulin, switching them to SHR-3167 or insulin degludec, the more rigorous comparator because degludec sets the modern bar for ultra-long-acting basal; primary endpoint is HbA1c change at week 16 [2]. Three Phase 1 studies support the program: a euglycemic clamp study in healthy subjects against glargine (NCT07588906, completed, n=24) [3], a relative bioavailability study currently recruiting (NCT07489482, n=60 estimated) [4], and a steady-state PK/PD characterization in T2D patients with insulin degludec as the reference, currently recruiting (NCT07032688, n=55 estimated) [5]. No FDA designations. Hengrui has not filed an IND (Investigational New Drug - the US regulatory filing that authorizes human trials) in the US for this program. The drug is novel to humans (NLM assigned RxNorm CUI 2670812), but the molecular structure and class have not been disclosed in any public Hengrui filing. That opacity is normal for Chinese pharma at this stage; the company tends to disclose more after Phase 3 initiation or a partnership. Expected Phase 2 readout: Q4 2026 to Q2 2027 based on enrollment completion timing.

Trial design strongly implies SHR-3167 is a long-acting basal insulin analog, a tailored copy of the human insulin molecule engineered to be absorbed slowly from the injection site so it delivers steady 24-hour glucose control. Here's the biology in plain English: insulin is the hormone your pancreas makes to tell your liver "stop dumping glucose into the blood" and your muscle and fat to "soak up glucose now." In type 2 diabetes, the pancreas eventually wears out, and patients need injected insulin to keep blood sugar in range, especially overnight and between meals, when basal (background) insulin coverage is the job. The drug class is bedrock validated: insulin therapy has been standard since 1922, and the insulin receptor (INSR) is the single most well-characterized hormone receptor in human biology. The engineering question, where products differentiate, is duration and flatness of action. Glargine uses a pH trick (precipitates at neutral pH after subcutaneous injection); degludec uses a fatty-acid tail that hooks onto albumin and forms multi-hexamer chains that release insulin slowly [6]. We don't know which trick Hengrui used. The euglycemic clamp study (NCT07588906) is the technique that will tell us: glucose is infused intravenously to keep blood sugar constant while measuring how much extra insulin is needed minute-by-minute - the resulting glucose infusion rate (GIR) curve over time directly reveals the drug's potency, duration, and flatness of action. The bar SHR-3167 needs to clear is non-inferior HbA1c reduction with a hypoglycemia profile at least as good as degludec. Degludec's hypo advantage over glargine is the modern competitive benchmark.

The lead Phase 2, NCT06688123, is a treat-to-target study: both arms titrate to a fasting plasma glucose target, then compare HbA1c reduction at week 20 [1]. This is exactly the design regulators want for basal insulin approval, because it isolates the drug's effect from titration discipline by having both arms aim at the same fasting glucose. With n=275 and a non-inferiority margin typically set at 0.4% HbA1c, the trial is statistically powered for a clear yes/no on equivalence with glargine. Active-not-recruiting status means readout is mechanical from here. The second Phase 2, NCT07018453, is more interesting: 173 patients already on basal insulin switched to SHR-3167 or degludec, with HbA1c change at week 16 as the primary endpoint [2]. Degludec is the toughest comparator in this market. Head-to-head superiority over degludec on hypoglycemia would be a real differentiator; non-inferiority is the realistic bet. The Phase 1 euglycemic clamp study (NCT07588906) directly characterizes the PK/PD profile (PK = pharmacokinetics, how the drug moves through and is cleared from the body; PD = pharmacodynamics, the biological effect - for insulin, blood glucose lowering) against glargine using glucose infusion rate AUC as the primary readout; the trial is completed but results are not yet public [3]. That clamp data, once disclosed, will tell us more about the molecule than the Phase 2 outcomes will, because it shows the actual shape of the action curve. Trial design quality: conventional and appropriate for a basal insulin program. No red flags. Hengrui has built basal insulin trials before, and the design choices reflect that experience.

The model estimates a 12% chance this drug is eventually approved. It starts from the historical approval rate for Phase 2 drugs in this area - about 35% - then adjusts based on ten facts about the trial and sponsor. Two factors push the number up: larger-than-typical enrollment and an open-label trial design. Two factors pull it back down: the sponsor's thin approval record and weak earlier-phase results, while the remaining facts fall near average for this stage.

Efficacy risk is low. Basal insulin analogs almost always hit their HbA1c endpoint when titrated to target, because the endpoint is essentially a function of titration discipline. The real efficacy question is the PK profile: if SHR-3167's action curve is less flat than glargine's, hypoglycemia rates will be worse, and non-inferiority on safety becomes the gating issue. Safety risk is class-defined: hypoglycemia (especially nocturnal), weight gain, injection-site reactions. No black box territory for the class, but the bar degludec set is high. Execution risk: low. Hengrui has run basal insulin trials before, and active-not-recruiting status across both Phase 2 studies says enrollment is done [1][2]. Regulatory risk: NMPA (National Medical Products Administration, China's drug regulator, the FDA equivalent) approval in China is the realistic path; NMPA reviews of insulin analogs from established domestic sponsors typically run 12-18 months post-submission. FDA/EMA expansion would require bridging studies and IND filings Hengrui has not announced. Commercial risk is the biggest threat to the asset's value. The basal insulin market is being eaten on two sides. From below: biosimilar glargine has driven dramatic price erosion - Mylan/Biocon's Semglee launched in August 2020 at ~$30-35/pen, roughly a 65-70% discount to Lantus, and net glargine prices have been declining ~$0.67 per quarter since Basaglar's approval [11]. From above: once-weekly insulins are real, not hypothetical. Novo's icodec (Awiqli) holds EMA marketing authorization since May 2024 [7], and Lilly's efsitora alfa completed Phase 3 (QWINT program) in 2025 with regulatory submissions to US/EU/Japan filed by year-end 2025 [8]. If once-weekly insulins prove out on real-world safety and convenience, the daily basal insulin TAM (total addressable market - the global revenue pool the product can compete for) shrinks fast. SHR-3167 needs to either be cheaper than glargine biosimilars in emerging markets, or be a stepping stone to a Hengrui weekly insulin. A sole-asset daily basal insulin in 2027 is a tough business case ex-China.

Worth watching at low priority. This is execution-risk pharma, not science-risk pharma. The mechanism is bedrock, the trial design is correct, and Hengrui executes. China context matters here: the country has roughly 140 million adults with diagnosed diabetes (the world's largest diabetes population), insulin still represents the largest share (~46%) of the China diabetes drugs market, and Sanofi's Lantus has historically been the dominant premium basal - though domestic manufacturers (Gan & Lee, Tonghua Dongbao) have captured >50% of public hospital insulin volumes by 2025 [12]. Hengrui has invested in insulin biosimilar bioprocessing capacity, so SHR-3167 fits an existing manufacturing and commercial footprint rather than being a one-off. The interesting signal isn't the Phase 2 HbA1c outcome (likely positive) but two adjacent data points: the Phase 1 euglycemic clamp results (NCT07588906) when they're published, because the action curve shape will reveal whether SHR-3167 is competitive with degludec or just glargine-class [3]; and whether Hengrui announces a Phase 3 site footprint outside China, which would signal serious global ambitions. Check back when the clamp data publishes or when Phase 2 readouts drop. Q4 2026 to Q2 2027 is the realistic window. The bigger question worth tracking: does Hengrui have a once-weekly insulin in earlier development? We were not able to confirm one in the public record. If SHR-3167 is just a daily basal placeholder while they build a weekly molecule, the strategic picture changes entirely. Right now, this is a single asset in a market where the durable winners will be the companies with weekly insulin in late-stage development. Hengrui needs to be one of them.